Gynecologic Cancers

The confirmed ORR in the investigational arm was 52.3% vs 46.6% in the chemotherapy arm, with respective complete response rates of 10.9% and 8.5%.

In terms of OS among patients with non-tBRCA–mutated, HRD-positive disease, the median value was not reached in either durvalumab arm.

Data from the ROSELLA trial show a consistent benefit with relacorilant plus nab-paclitaxel across PROC subgroups.

A significant survival improvement was observed among patients with dMMR carcinomas who received atezolizumab/chemotherapy.

Data from the NAPISTAR1-01 study showed enduring benefit with TUB-040 among those with platinum-resistant high-grade serous ovarian cancer.

Results from the phase 3 KEYNOTE-B96 trial showed favorable results with pembrolizumab-based therapy in this ovarian cancer population.

The safety profile of pembrolizumab plus chemotherapy with or without bevacizumab was consistent with that observed in previous studies.

The most pronounced overall and recurrence-free survival benefit with chemoradiotherapy was observed among patients with TP53-abnormal endometrial cancer.

Artificial intelligence can be used to automate genetic counseling processes and streamline a patient’s communication with relatives regarding genetic risk.

IMNN-001 exhibits prolonged favorable safety among patients with advanced newly diagnosed ovarian cancer.

Findings from a phase 1 trial and the REJOICE-Ovarian01 trials supported the FDA’s decision to grant the designation to R-DXd in those with gynecologic cancers.

The FDA has assigned a Prescription Drug User Fee Act date of July 11, 2026, for relacorilant as a treatment for platinum-resistant ovarian cancer.

Patients with recurrent or metastatic cervical cancer in Hong Kong are now eligible to receive treatment with tisotumab vedotin.

Results from the phase 3 MIRASOL trial led to the approval of mirvetuximab soravtansine for patients with FRα+ ovarian cancer.

Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.

Among 115 patients treated with avutometinib and defactinib, only 5 deaths occurred in the study, none of which were related to study treatment.

The use of 68Ga pentixafor complements fluorodeoxyglucose and had no correlation with CXCR4 immunohistochemistry.

More than 80% of patients who were screened for cervical cancer and provided with a self-collection kit did so by utilizing the kit.

For patients with unresectable vulvar cancer, an improved ORR was observed with pembrolizumab plus cisplatin and RT followed by maintenance pembrolizumab.

Less radical surgery did not come at the expense of postoperative metrics, including 30-day readmissions, surgical findings, or receipt of adjuvant therapy.

The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

Certain subpopulations experienced significantly poorer outcomes in 2020, highlighting concerns regarding access to care.

Socioeconomic or racial disparities may contribute to unchanged overall survival among certain patients with metastatic uterine cancer.

Despite all groups completing chemoradiation within 56 days, delays contributed to a nonsignificant difference in length between Black vs White patients.

The adverse effect profile of abemaciclib plus hormonal therapy was comparable with prior reports of CDK4/6 inhibitors.

Puxitatug samrotecan was well tolerated in patients with advanced or metastatic endometrial cancer.

A slightly higher complete response rate was observed with the metformin regimen vs with the levonorgestrel-releasing IUD alone in endometrial cancer.

No deaths or significant adverse effects were reported in the screened population among those who received hysteroscopic resection for endometrial cancer.

Mirvetuximab soravtansine additionally showcased PFS, ORR, and DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.

The phase 2 trial is currently accruing additional patients with advanced mesonephric gynecologic cancer for treatment with avutometinib/defactinib.